Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Publisher Name :
Date: 01-Dec-2016
No. of pages: 65

Hepatitis C market has witnessed a historically rare market penetration in terms of the breadth and quality of several strongly innovative and very competitive new products, known as direct-acting antivirals (DAA). The latest DAA combination therapies, such as Harvoni, Zepatier and Epclusa, have been shown to clear hepatitis C virus (HCV) infection in over 90% of treated individuals, demonstrating superior efficacy and tolerability compared with interferon-based therapy and older-generation DAAs.

Hepatitis C is a blood-borne viral infection characterized by chronic inflammation of the liver. Although patients may be asymptomatic for a number of years or decades, chronic HCV infection can lead to liver fibrosis (formation of scar tissue) and ultimately liver cirrhosis, in which permanent fibrotic scar tissue replaces healthy liver cells. In severe cases, cirrhosis may lead to liver failure and death. In addition, hepatitis C patients are at an increased risk of developing liver cancer.

Despite the entry of new therapies, there is a subgroup of patients that do not respond to current treatments, or relapse. In addition, HCV resistance to DAAs may also be a cause for concern, as the development of selection pressure by the host immune system in combination with DAA therapy may lead to outgrowth of resistant viruses. As such, the rationale for investment in first-in-class innovation remains strong.

Recent years have seen a revolution in hepatitis C therapeutic development, and the treatment algorithms have rapidly shifted away from interferon-based therapies and towards interferon-free direct-acting antiviral (DAA) combination therapies. Compared with the older treatments, DAA combination therapies have a favorable safety profile and excellent tolerability and efficacy, achieving cure rates of over 90%.

Although a number of highly effective products have entered the market in the last few years, hepatitis C remains a relatively attractive indication for a number of reasons. There is a large patient population that has unmet needs due to being unresponsive or relapsing following treatment. In addition, the high therapy costs of the newer treatments present a major barrier to care.

The report “Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations” allows you to appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options and algorithms.

In depth, it provides the following:


  • Visualize the composition of the hepatitis C market in terms of dominant classes of therapies. Key unmet needs are identified to allow a competitive understanding of gaps in the market.

  • Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.

  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix tailored to hepatitis C, all first-in-class targets in the hepatitis C pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Executive Summary 5
2.1 Unmet Needs Remain in Hepatitis C Market 5
2.2 Pipeline Dominated by Direct-Acting Antivirals with Small Number of First-in-Class Products 5
2.3 Diverse Range of Host-Targeting and Direct-Acting Antivirals in First-in-Class Pipeline 5

3 The Case for Innovation 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Development Remains Attractive 7
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 8
3.6 GBI Research Report Guidance 9

4 Clinical and Commercial Landscape 10
4.1 Disease Overview 10
4.2 Disease Symptoms 10
4.3 Epidemiology 10
4.4 Etiology and Risk Factors 11
4.5 Pathophysiology 12
4.6 Disease Progression 14
4.6.1 Acute Stage 14
4.6.2 Chronic Stage 14
4.6.3 End Stage 15
4.6.4 Factors Affecting Progression 15
4.7 Co-morbidities and Complications 15
4.8 Diagnosis 15
4.9 Treatment Options and Treatment Algorithm 16
4.9.1 Treatment Options 16
4.9.2 Treatment Algorithm 18
4.10 Overview of Marketed Products in Hepatitis C 20
4.10.1 Molecule Type and Molecular Target Analysis 20

5 Assessment of Pipeline Product Innovation 21
5.1 Pipeline by Stage of Development, Molecule Type and Molecular Target 21
5.2 Comparative Distribution of Programs between the Hepatitis C Market and Pipeline by Therapeutic Target Family 23
5.3 First-in-Class Programs Targeting Novel Molecular Targets 24
6 Signaling Network, Disease Causation and Innovation Alignment 33
6.1 Complexity of Signaling Networks in Hepatitis C 33
6.2 Signaling Pathways and First-in-Class Molecular Target Integration 34
6.3 First-in-Class Matrix Assessment 34

7 First-in-Class Target Evaluation 37
7.1 Viral Targets 37
7.1.1 Pipeline Programs Targeting HCV P7 37
7.1.2 Pipeline Programs Targeting HCV Envelope Proteins E1 and E2 38
7.1.3 Pipeline Programs Targeting HCV NS4B 40
7.2 Host Targets 41
7.2.1 Pipeline Programs Targeting MicroRNA 122 41
7.2.2 Pipeline Programs Targeting Toll-like Receptor 3 43
7.2.3 Pipeline Programs Targeting Claudin 1 43
7.2.4 Pipeline Programs Targeting Serine C-Palmitoyltransferase 45
7.2.5 Pipeline Programs Targeting Type III Phosphatidylinositol 4-Kinase Beta 45
7.2.6 Pipeline Programs Targeting Caspases 46

8 Strategic Consolidations 50
8.1 Industry-Wide First-in-Class Deals 50
8.2 Licensing Deals 51
8.3 Co-development Deals 54
8.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals 57

9 Appendix 59
9.1 References 59
9.2 Abbreviations 63
9.3 Research Methodology 64
9.4 Secondary Research 64
9.4.1 Market Analysis 64
9.4.2 Pipeline Analysis 64
9.4.3 First-in-Class Matrix Assessment 65
9.4.4 First-in-Class Target Profiles 65
9.4.5 Licensing and Co-Development Deals 65
9.5 Contact Us 65
9.6 Disclaimer 65

List of Tables

Table 1: Hepatitis C Therapeutics Market, Risk Factors for Fibrosis Progression, 2016 15
Table 2: Hepatitis C Therapeutics Market, Global, Characteristics of DAAs, 2016 17
Table 3: Hepatitis C Therapeutics Market, Global, Categories of Approved DAA Therapies in Hepatitis C, 2016 18
Table 4: Hepatitis C Therapeutics Market, Global, AASLD/IDSA Hepatitis C Treatment Guidelines, 2016 19
Table 5: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of HCV P7, 2016 37
Table 6: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting HCV P7, 2016 38
Table 7: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of HCV Envelope Protein E1 and E2, 2016 38
Table 8: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting HCV Envelope Protein E1 and E2, 2016 39
Table 9: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of HCV Envelope Protein E2, 2016 39
Table 10: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting HCV Envelope Protein E2, 2016 39
Table 11: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of HCV NS4B, 2016 41
Table 12: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting HCV NS4B, 2016 41
Table 13: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of MicroRNA 122, 2016 42
Table 14: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting MicroRNA 122, 2016 42
Table 15: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Toll-like Receptor 3, 2016 43
Table 16: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting Toll-like Receptor 3, 2016 43
Table 17: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Claudin 1, 2016 44
Table 18: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting Claudin 1, 2016 44
Table 19: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Serine C-Palmitoyltransferase, 2016 45
Table 20: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting Serine C-Palmitoyltransferase, 2016 45
Table 21: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Type III Phosphatidylinositol 4-Kinase Beta, 2016 46
Table 22: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting Type III Phosphatidylinositol 4-Kinase Beta, 2016 46
Table 23: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 1, 2016 47
Table 24: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 2, 2016 47
Table 25: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 3, 2016 47
Table 26: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 5, 2016 48
Table 27: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 6, 2016 48
Table 28: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 7, 2016 48
Table 29: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 8, 2016 48
Table 30: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 9, 2016 49
Table 31: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting Caspases, 2016 49
Table 32: Abbreviations 63

List of Figures

Figure 1: Hepatitis C Therapeutics Market, US, Innovation Trends in Product Approvals, Number of Product Approvals by FDA and Five-Year Moving Average of Product Approvals, 1987-2014 6
Figure 2: Hepatitis C Therapeutics Market, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval ($m), 2006-2013 8
Figure 3: Hepatitis C Therapeutics Market, Major Markets, Hepatitis C Prevalent Population (million), 2015-2022 11
Figure 4: Hepatitis C Therapeutics Market, Major Markets, Hepatitis C Treatment Rate (‘000), 2015-2022 11
Figure 5: Hepatitis C Therapeutics Market, HCV Genomic RNA, 2016 13
Figure 6: Hepatitis C Therapeutics Market, Global, Marketed Products by Molecule Type and Molecular Target, 2016 20
Figure 7: Hepatitis C Therapeutics Market, Global, Pipeline by Stage of Development and Molecule Type, 2016 21
Figure 8: Hepatitis C Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016 23
Figure 9: Hepatitis C Therapeutics Market, Global, Distribution of Molecular Targets Across Pipeline and Marketed Products, 2016 24
Figure 10: Hepatitis C Therapeutics Market, Global, Distribution of Pipeline First-in-Class and Established Products, 2016 25
Figure 11: Hepatitis C Therapeutics Market, Global, Percentage Distribution of First-in-Class and Established Pipeline Products by Stage of Development (%), 2016 25
Figure 12: Hepatitis C Therapeutics Market, Global, Percentage Distribution of First-in-Class and Established Pipeline Products by Molecular Target (%), 2016 26
Figure 13: Hepatitis C Therapeutics Market, Global, Pipeline Products, 2016 (Part 1) 27
Figure 14: Hepatitis C Therapeutics Market, Global, Pipeline Products, 2016 (Part 2) 28
Figure 15: Hepatitis C Therapeutics Market, Global, Pipeline Products, 2016 (Part 3) 29
Figure 16: Hepatitis C Therapeutics Market, Global, Pipeline Products, 2016 (Part 4) 30
Figure 17: Hepatitis C Therapeutics Market, Global, Pipeline Products, 2016 (Part 5) 31
Figure 18: Hepatitis C Therapeutics Market, Global, Pipeline Products, 2016 (Part 6) 32
Figure 19: Hepatitis C Therapeutics Market, Global, First-in-Class Molecular Target for Host Factors Matrix Assessment, 2016 35
Figure 20: Hepatitis C Therapeutics Market, Global, First-in-Class Molecular Target for Viral Proteins Matrix Assessment, 2016 36
Figure 21: Hepatitis C Therapeutics Market, Global, Industry-Wide Deals by Stage of Development, 2006-2014 50
Figure 22: Hepatitis C Therapeutics Market, Global, Industry-Wide Licensing Deals by Deal Value ($m), Upfront Payment Value ($m) and Stage of Development, 2006-2014 51
Figure 23: Hepatitis C Therapeutics Market, Global, Licensing Deals by Region and Deal Value ($m), 2006-2016 52
Figure 24: Hepatitis C Therapeutics Market, Global, Disclosed and Undisclosed Licensing Deals by Year, Total Disclosed Deal Value ($m) and Total Upfront Payment Value ($m), 2006-2015 52
Figure 25: Hepatitis C Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2016 53
Figure 26: Hepatitis C Therapeutics Market, Frequency and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target, Global, 2006-2016 54
Figure 27: Hepatitis C Therapeutics Market, Global, Co-development Deals by Region and Deal Value ($m), 2006-2016 55
Figure 28: Hepatitis C Therapeutics Market, Global, Disclosed and Undisclosed Co-development Deals by Year, Total Disclosed Deal Value ($m) and Total Upfront Payment Value ($m), 2006-2015 55
Figure 29: Hepatitis C Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2016 56
Figure 30: Hepatitis C Therapeutics Market, Global, Frequency and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target, 2006-2016 57
Figure 31: Hepatitis C Therapeutics Market, Global, First-in-Class Programs with No Recorded Prior Deal Involvement, 2016 58
Figure 32: Hepatitis C Therapeutics Market, Global, First-in-Class Programs with Prior Deal Involvement, 2016 58

  • Global Prophylactic Hepatitis B Virus Vaccines Market Research Report 2020, Segment by Key Companies, Countries, Types, Applications and Forecast 2021 to 2026
    Published: 12-Feb-2020        Price: US 3200 Onwards        Pages: 179
    According to HJ Research's study, the global Prophylactic Hepatitis B Virus Vaccines market is estimated to be valued at XX Million US$ in 2019 and is projected to reach XX Million US$ by 2026, expanding at a CAGR of XX% during the forecast period. The report on Prophylactic Hepatitis B Virus Vaccines market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, industrial chain, etc. In this study, 2019 has ......
  • Thymosin Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 09-Feb-2020        Price: US 3000 Onwards        Pages: 143
    Thymosin Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Thymosin industry with a focus on the Chinese market. The report provides key statistics on the market status of the Thymosin manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2014-2024 global and Chinese Thymosin market covering all important ......
  • Thymosin alpha 1 Antibody Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 09-Feb-2020        Price: US 3000 Onwards        Pages: 138
    Thymosin alpha 1 Antibody Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Thymosin alpha 1 Antibody industry with a focus on the Chinese market. The report provides key statistics on the market status of the Thymosin alpha 1 Antibody manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2014-2024 global ......
  • Thymosin beta 4 Antibody Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 09-Feb-2020        Price: US 3000 Onwards        Pages: 147
    Thymosin beta 4 Antibody Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Thymosin beta 4 Antibody industry with a focus on the Chinese market. The report provides key statistics on the market status of the Thymosin beta 4 Antibody manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2014-2024 global and......
  • Alcoholic Hepatitis Drugs Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 08-Feb-2020        Price: US 3000 Onwards        Pages: 135
    Alcoholic Hepatitis Drugs Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Alcoholic Hepatitis Drugs industry with a focus on the Chinese market. The report provides key statistics on the market status of the Alcoholic Hepatitis Drugs manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2014-2024 global ......
  • Global Hepatitis A Vaccine Market Research Report 2020, Segment by Key Companies, Countries, Types, Applications and Forecast 2021 to 2026
    Published: 22-Jan-2020        Price: US 3200 Onwards        Pages: 180
    According to HJ Research's study, the global Hepatitis A Vaccine market is estimated to be valued at XX Million US$ in 2019 and is projected to reach XX Million US$ by 2026, expanding at a CAGR of XX% during the forecast period. The report on Hepatitis A Vaccine market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, industrial chain, etc. In this study, 2019 has been considered as the base year and 202......
  • Global Hepatitis A Vaccine Market Data Survey Report 2015-2025
    Published: 21-Jan-2020        Price: US 1500 Onwards        Pages: 65
    Summary The global Hepatitis A Vaccine market will reach xxx Million USD in 2020 with CAGR xx% 2020-2025. The main contents of the report including: Global market size and forecast Regional market size, production data and export & import Key manufacturers profile, products & services, sales data of business Global market size by Major End-Use Global market size by Major Type Key manufacturers are included based on company profile,......
  • Global Hepatitis A Vaccine Market Analysis 2015-2019 and Forecast 2020-2025
    Published: 16-Jan-2020        Price: US 2980 Onwards        Pages: 82
    Snapshot The global Hepatitis A Vaccine market size is estimated at xxx million USD with a CAGR xx% from 2015-2019 and is expected to reach xxx Million USD in 2020 with a CAGR xx% from 2020 to 2025. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Hepatitis A Vaccine by product, region and application, in addition, this report introduces market competition situation among the vendors and comp......
  • Global Thymosin a1 Market Research Report 2020
    Published: 14-Jan-2020        Price: US 2900 Onwards        Pages: 91
    The global Thymosin a1 market is valued at xx million US$ in 2020 is expected to reach xx million US$ by the end of 2026, growing at a CAGR of xx% during 2021-2026. This report focuses on Thymosin a1 volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Thymosin a1 market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Eu......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs